Humanin Reconstitution Calculator

No. Humanin and its analogs (S14G-humanin/HNG, colivelin) have no FDA approval and no completed human efficacy trials; published human data are purely observational biomarker studies (observational). Preclinical evidence supports cytoprotection across neurodegenerative, cardiovascular, and metabolic disease models, and the field remains at that development stage. Circulating humanin declines with age across species and is lower in Alzheimer's disease and mitochondrial disease, which drives interest in replacement strategies, but this remains an untested hypothesis in humans.

Subcutaneous injection is the default route for systemic research (community protocol). Oral use is unsupported: humanin is a 24-amino-acid peptide cleaved by prolyl endopeptidase, consistent with poor oral survival, and no oral formulation has been published (mechanistic). Documented routes include subcutaneous infusion (1 mg/kg/day in rats), intraperitoneal and intravenous injection, and intranasal delivery, which reaches the brain via trigeminal pathways and improved behavioral recovery in a Parkinson's disease mouse model (animal). Choose intranasal for CNS-focused protocols; subcutaneous for metabolic/systemic goals (community protocol).

HNG (S14G-humanin) is a single substitution (serine-14 → glycine) with roughly 1000-fold greater cytoprotective potency than native humanin and is the most-studied analog in disease models (in-vitro, animal). HNG is typically dosed 10–100× lower than native humanin (community protocol). Stability also differs: HNG remains ~95% intact after 28 days at 4°C in formulation buffer but degrades in plain water or PBS, forming oxidized and dimerized species, meaning the analog's practical reliability depends heavily on vehicle. Both are sold as research peptides; HNG is generally preferred for potency per milligram (community protocol).

No validated human dose exists; all efficacy dosing derives from rodents (animal). Representative regimens: HNG 2 mg/kg IV before reperfusion reduced renal ischemia-reperfusion injury in rats; HNG 0.4–4 mg/kg IP twice weekly was tested for retinal degeneration, with visual improvement only at 4 mg/kg; native humanin 4 mg/kg IP daily for 15 days was used in diabetic mice; HNG 4 mg/kg IP twice weekly for 14 months was used in aging mice. Allometric scaling (mouse factor ÷12.3) converts the common 4 mg/kg mouse dose to ~0.33 mg/kg human equivalent (~23 mg for 70 kg); community practice typically runs HNG 2.5–5 mg SC 2–3 times per week for longevity/general use, HNG 5–10 mg daily to every other day for higher-intensity protocols, and native humanin 10–20 mg 2–3 times per week (community protocol).

Cancer: treat as contraindicated. Systemic humanin accelerated tumor growth and lung metastasis while blunting chemotherapy in a triple-negative breast cancer mouse model; humanin drives temozolomide chemoresistance in glioblastoma via FPR2/GP130 signaling (animal); serum humanin is significantly elevated in breast cancer patients versus controls, consistent with a tumor-supportive role (observational). Avoid with any active malignancy or significant cancer risk factors (community protocol).

Pregnancy: no human or animal safety data exist for exogenous humanin administration (animal/observational). Placental humanin and SHLP levels are reduced in gestational diabetes and track maternal insulin resistance, but this does not establish that supplementation is safe or beneficial. Avoid during pregnancy and lactation (community protocol).

The longest published exposure is HNG 4 mg/kg IP twice weekly for 14 months in mice, which reduced age-related myocardial fibrosis with no reported adverse effects, though formal toxicology was not performed (animal). Published regimens otherwise span single-dose rescue protocols to 15-day daily courses; no human duration data exist. Because circulating humanin declines with age, continuous or long-cycle use has a mechanistic rationale, but community practice typically cycles 8–12 weeks on with 2–4-week breaks pending human data (community protocol).

Yes. HNG in formulation vehicle retains ~95% intact peptide after 28 days at 4°C but degrades rapidly at 37°C and in unbuffered water or PBS, generating singly/doubly oxidized and homodimerized species. Store lyophilized vials frozen (about −20°C) and reconstituted solution refrigerated (2–8°C); avoid repeated freeze-thaw cycles and heat exposure during travel (community protocol). Use reconstituted solution within ~28 days and discard if cloudy or precipitating, which may indicate fibrillar aggregation (community protocol).